Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 28.92M 25.28M 23.33M 21.5M 40.52M 2.79B 41.42M 279M 110M 1.36B 109M 106M 4.7B P/E 2026 *
-1.09x
P/E 2027 * -1.65x
Enterprise Value 28.92M 25.28M 23.33M 21.5M 40.52M 2.79B 41.42M 279M 110M 1.36B 109M 106M 4.7B EV / Sales 2026 *
-
EV / Sales 2027 * 2.24x
Free-Float
97.65%
Yield 2026 *
-
Yield 2027 * -
06-03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
06-01 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
06-01 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
05-29 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
05-29 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
05-08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
04-22 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
04-22 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
04-06 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
03-30 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-17 CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 CI
02-13 Actinium Pharmaceuticals, Inc. Announces Executive Changes, Effective as of February 27, 2026 CI
1 day+3.58%
1 week-0.87%
Current month-5.93%
1 month-10.50%
3 months-29.08%
6 months-30.68%
Current year-32.21%
1 week 0.88
Extreme 0.88
0.93
1 month 0.88
Extreme 0.88
1.05
Current year 0.88
Extreme 0.88
1.53
1 year 0.88
Extreme 0.88
1.89
3 years 0.88
Extreme 0.88
10.24
5 years 0.88
Extreme 0.88
15.12
10 years 0.88
Extreme 0.88
64.5
Manager TitleAgeSince
Chief Executive Officer 62 08/06/2017
Chief Tech/Sci/R&D Officer - 31/05/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 31/12/2007
Chairman 62 30/09/2013
Director/Board Member 68 07/11/2013
Date Insider Type Main position Quantity % Market Cap.
18/08/25 Tax

Chief Executive Officer

120,900 0.3876%
31/03/25 Issuer sale

Director

184,984 0.5930%
31/03/25 Issuer sale

Director

182,484 0.5850%
Change 5-day change 1-year change 3-year change Capi.($)
+3.58%-0.87%-46.09%-87.27% 28.92M
-0.82%-1.76%+54.49%+55.85% 53.83B
-7.17%-4.39%+42.72%+73.70% 52.1B
+0.80%-6.31%+5.62%+413.12% 23.48B
-0.09%-0.01%-16.85%-16.17% 23.13B
+3.46%+2.52%+36.64%-5.41% 19.36B
-0.03%-1.71%+34.46%-32.43% 17.56B
-5.16%-7.00%+168.44%+291.24% 15.2B
+3.62%0.00%+33.47%+643.91% 14.83B
+0.43%-1.03%+25.75%+186.18% 14.06B
Average -0.13%-2.45%+33.87%+152.27% 23.36B
Weighted average by Cap. -1.50%-2.36%+41.24%+137.37%

Financials

2026 *2027 *
Net sales - 12.93M 11.3M 10.42M 9.61M 18.11M 1.24B 18.51M 125M 49.01M 610M 48.55M 47.48M 2.1B
Net income -28.5M -24.91M -22.98M -21.18M -39.93M -2.74B -40.81M -275M -108M -1.34B -107M -105M -4.63B -23.27M -20.33M -18.76M -17.3M -32.6M -2.24B -33.32M -224M -88.21M -1.1B -87.38M -85.47M -3.78B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
25
Date Price Change Volume
17/07/26 US$0.9219 +3.58% 56,470
16/07/26 US$0.8900 -3.25% 64,837
15/07/26 US$0.9199 +2.77% 32,576
14/07/26 US$0.8951 -1.09% 123,131
13/07/26 US$0.9050 -2.69% 96,428
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9219USD
Average target price
5.000USD
Spread / Average Target
+442.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock